MONTREAL, July 10, 2017 /CNW/ - enGene Inc., a biotechnology company focused on the development of a proprietary oral gene therapy platform, today announced the appointment of Steve Gannon as an independent director on its Board of Directors. Mr. Gannon will also serve as the Chairman of the Company's Audit Committee.
Mr. Gannon brings to enGene a wealth of financial and operational expertise and close to 30 years of leadership experience in the biopharmaceutical industry. Mr. Gannon was Chief Financial Officer, Senior Vice President of Finance and Treasurer at Aptalis Pharma Inc. until February 2014, when it was acquired by Forest Laboratories Inc. Prior to joining Aptalis, Mr. Gannon served as the Chief Financial Officer for Cryocath Technologies Inc., which was acquired by Medtronic Inc. in 2007. Prior to Cryocath, Mr. Gannon served as Head of Finance and Administration of the Research Division of AstraZeneca Canada Inc. and Chief Financial Officer of Mallinckrodt Medical Inc.'s Canadian operations. Mr. Gannon is currently on the boards of directors of Advanced Accelerator Applications SA and Xenon Pharmaceuticals, both Nasdaq-traded biotechnology companies, as well as Laborie Medical Technologies, a private medical device company. He received a bachelor of commerce from Concordia University in Montreal, and completed the Executive MBA Program at the Richard Ivey School of Business at the University of Western Ontario.
"Mr. Gannon's impressive track record in corporate finance, business development and strategic transactions in the healthcare sector, will be extremely valuable to enGene as we embark on our next phase of development in advancing our game-changing Gene Pill™ platform to clinical testing and expanding its application in new indications," said Dr. Anthony T. Cheung, President and CEO of enGene.
"This is an exciting period of growth for the company and I look forward to contributing to the delivery of its groundbreaking gene therapy platform to market," said Mr. Gannon.
enGene Inc. is a biotechnology company developing a robust proprietary gene-therapy platform for localized delivery of immune-modulating proteins to mucosal cells lining the gut for the oral treatment of various immune disorders. enGene has developed a unique gut-optimized gene delivery formulation into an orally available Gene Pill™, which has the potential to be a game-changing platform to provide oral delivery of a wide range of protein drugs. enGene has established global strategic alliances with two of the world's largest pharmaceutical companies.
Renseignements: Dr. Anthony Cheung, President and CEO, enGene Inc., email@example.com, Office: (514) 332-4888, ext. 204